You are here: Industry Insights > AbbVie

News List

AbbVie loses bid to hoard documents in Humira patent fight with Boehringer fiercepharma
February 24, 2019
Boehringer Ingelheim is one of the only—if not the only—biosimilar makers still challenging AbbVie’s Humira patents in court. And the German drugmaker just won a skirmish in that high-stakes battle, gaining access to documents AbbVie had fought to keep se
Pfizer dethrones AbbVie as Xeljanz soars past Humira in January TV spending fiercepharma
February 24, 2019
New year, new leader on the pharma TV ad spending board. In January, Pfizer’s Xeljanz topped AbbVie's Humira in a rare bypass of the usual No. 1, spending more than $40 million on national TV time.
Following deal focused on Alzheimer's disease, AbbVie, Voyager Therapeutics expand collaboration to Parkinson's disease firstwordpharma
February 23, 2019
AbbVie entered an exclusive global agreement with Voyager Therapeutics to develop vectorised antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases characterised by the abnormal
AbbVie’s JAK inhibitor upadacitinib gets Priority Review pharmaphorum
February 21, 2019
AbbVie’s attempts to diversify beyond Humira have been boosted as its investigational drug upadacitinib has been granted Priority Review by the FDA for moderate to severe rheumatoid arthritis (RA).
FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis pharmaceutical-technology
February 21, 2019
The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted by AbbVie for its investigational medicine upadacitinib to treat adults with moderate to severe rheumatoid arthritis....
Humira Topped for Seven Times in Sales and Remaining Global Drug King PharmaSources/1℃
February 13, 2019
The 2018 sales of Humira reached USD19.936 billion, securing its position as the global drug king and topping for seven times in terms of sales!
AbbVie and Teneobio to co-develop new drug for multiple myeloma pharmaceutical-technology
February 13, 2019
AbbVie has entered a strategic collaboration with biotechnology company Teneobio and its affiliate TeneoOne for the development and commercialisation of a multiple myeloma candidate TNB-383B.....
Global Humira sales near $20bn, but expect decline in 2019 bioprocessintl
February 03, 2019
Looking to 2019, AbbVie says US sales of its bestseller monoclonal antibody Humira (adalimumab) will continue to grow but expects a $2 billion hit from biosimilar competition.
AbbVie warns of bigger hit to Humira sales this year as biosimilar competition dents Q4 results firstwordpharma
January 28, 2019
AbbVie noted that the fourth-quarter loss was due to a $4.1-billion impairment charge related to intangible assets acquired as part of the acquisition of Stemcentrx in 2016 for $5.8 billion.
AbbVie warns of bigger hit to Humira sales this year as biosimilar competition dents Q4 results firstwordpharma
January 28, 2019
AbbVie noted that the fourth-quarter loss was due to a $4.1-billion impairment charge related to intangible assets acquired as part of the acquisition of Stemcentrx in 2016 for $5.8 billion.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page